SCHAUMBURG, Ill., July 24 /EMWNews/ -- Sagent Pharmaceuticals, Inc.,

a privately-held specialty pharmaceutical company, today announced that it

has launched ceftazidime for injection, USP, a semisynthetic

broad-spectrum, beta-lactam antibiotic. Sagent will offer ceftazidime in 1

and 2g single dose vials and 6g pharmacy bulk package vials. According to

IMS data, 2007 sales of injectable amiodarone in the United States were

approximately $45.7 million.



    "Sagent is proud to be providing tools to the healthcare community that

have the potential to help reduce medical errors," said Jeffrey M. Yordon,

chief executive officer, founder, and chairman of the board of Sagent. "We

are excited to make important products like ceftazidime available with

exciting innovations, such as easy-to-read dosage strengths and precise

lettering on vial labels that are intended to promote patient safety."



    Sagent's introduction of ceftazidime to the U.S. market is the seventh

product launched from Sagent's pipeline of more than 200 products this

year.

    About Ceftazidime



    Ceftazidime for Injection, USP is a semisynthetic broad-spectrum,

beta-lactam antibiotic used to treat bacterial infections, including

infections of the lower respiratory tract; skin and skin-structure; urinary

tract; bone and joint; and central nervous system. Ceftazidime is also

indicated for bacterial septicemia, gynecologic infections, and

intra-abdominal infections. Sagent's ceftazidime is the generic equivalent

of GlaxoSmithKline's FORTAZ(R).



    The most common adverse effects include diarrhea, headache, stomach

pain, nausea, vomiting, and numbness or tingling of the skin. Less common

adverse effects include abnormal muscle movements, severe stomach cramps,

severe nausea or vomiting, bloody stools, severe diarrhea, decreased

urination, vaginal irritation or discharge, fever, white patches in the

mouth, hoarseness, jaundice, injection site reactions, vein inflammation

and red, swollen or blistered skin, seizures.



    About Sagent Pharmaceuticals, Inc.



    Sagent Pharmaceuticals, founded in 2006, is a privately held specialty

pharmaceutical company focused on developing, manufacturing, sourcing and

marketing pharmaceutical products, with a specific emphasis on injectable

products. Sagent has created a unique, global network of resources,

comprised of rapid development capabilities, sophisticated manufacturing

and innovative drug-delivery technologies, quickly yielding an extensive

portfolio of pharmaceutical products that fulfills the evolving needs of

patients. Sagent currently has more than 200 products in development.



    To Discover Injectables Excellence(TM) and learn more about Sagent,

please visit http://www.SagentPharma.com.